At $1.9 billion, Chiesi is paying a significant premium to enter the hereditary angioedema market through its acquisition of KalVista Pharmaceuticals — a bet that oral, on-demand HAE treatment can displace the established injectable and prophylactic standard of care that BioCryst and Takeda currently dominate.
The logic is straightforward but the execution risk is real. KalVista’s lead asset, Ekterly (sebetralstat), is an oral plasma kallikrein inhibitor approved for on-demand treatment of HAE attacks. Chiesi already operates in rare diseases with a respiratory-focused portfolio, but HAE represents a deliberate push into immunology-adjacent rare conditions where patient lifetime value is extremely high and payer willingness to pay for convenience improvements — oral versus subcutaneous — is well established. The strategic fit is cleaner than most rare disease bolt-ons: Chiesi gets a commercial-stage product, a defined patient population, and a mechanism it did not previously own.
What makes the $1.9 billion figure striking is the competitive reality Ekterly enters. Berotralstat (BioCryst’s Orladeyo) already holds the oral prophylaxis position, and lanadelumab commands prophylactic injectable loyalty. Sebetralstat competes on a different axis — acute rescue, not prevention — which means Chiesi is not directly displacing Orladeyo but is instead targeting the attack-treatment segment still served largely by injectables like icatibant. That is a real market gap, but it requires physicians to reconfigure how they think about their HAE patients’ full treatment architecture, not just swap one pill for another. Commercial uptake will depend almost entirely on whether gastroenterology and immunology prescribers accept oral rescue as a behavioral replacement for a subcutaneous habit.
Chiesi is a privately held Italian group, which matters here: this deal does not require shareholder approval or create earnings-per-share pressure in the near term, giving the company patience most publicly traded acquirers cannot afford. The single number to track is Ekterly’s prescription share of the acute HAE treatment market at the 18-month post-acquisition mark — if oral rescue fails to convert a meaningful portion of injectable users by then, the $1.9 billion logic unravels faster than Chiesi’s private balance sheet can absorb.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
